Edit

Chiltern

https://www.chiltern.com/

Last activity: 21.08.2018

Active

Categories: BioTechBusinessGrowthHardwareIndustryMarketMedTechOfficeResearchService

Chiltern is a leading, global contract research organisation (“CRO”). The business offers a broad range of clinical CRO services for the pharmaceutical, biotech and medical device industries across a wide spectrum of therapeutic areas. The business serves its international client base from its office network across 35 countries. The CRO market has strong medium-term growth characteristics driven by: a continued increase in R&D spend by the biopharma industry; the growing worldwide regulatory burden associated with new drug applications; and, the continued trend to outsource CRO activities.
Kester Capital sold Chiltern in December 2013, generating a 2.2x return for Kester Capital funds.
www.chiltern.com

Mentions

Employees: 5001-10000

Founded date: 1982

Twitter

Facebook

Youtube

Investors 1

Date	Name	Website
-	Kester Cap...	kestercapi...

Mentions in press and media 23

Date	Title	Description
21.08.2018	Global CRO market to grow to $57 billion by 2024, report forecasts	The report attributed the anticipated growth to intensifying demand for new therapies and devices putting pressure on manufacturers’ research and development budgets, along with the increasing complexity of clinical trials and the regulatio...
31.07.2017	Term Sheet — Monday, July 31	GOING DIRECT I’m back! Huge thanks to Polina Marinova, Jen Wieczner and Robert Hackett for filling in. Today I’m diving into direct listings. Paid Content Securing the enterprise without boundaries From ExtraHop The reality has been a bit… ...
10.11.2015	Chiltern Firehouse head chef Nuno Mendes launches £1.75m Seedrs crowdfunding to re-open restaurant Viajante in Wapping
04.08.2005	EDC – perceptions standing in the way of progress?	Despite potential benefits offered by Electronic Data Capture (EDC) in clinical trials - uptake remains slow. And its concerns about how best to apply EDC to a project that seems to be the major obstacle, according to Debra Jendrasek, Manag...
08.02.2005	Chiltern makes early impact in India	Chiltern International is to take part in a major industry training programme in India designed to share knowledge and expertise on advanced clinical research and Good Clinical Practice. The company, one of the industry’s leading Independen...
02.02.2005	Shaking off Japan’s R&D jitters	Despite a slowing in growth over recent years and some key issues, the Japanese pharmaceutical market continues to offer huge potential, according to Dr Faiz Kermani of leading independent clinical research organization, Chiltern Internatio...
26.01.2005	Chiltern launches global EDC Solutions	Leading clinical research organisation Chiltern International is answering global demand for information, training and guidance on Electronic Data Capture with the launch of a new service – EDC Solutions The company, which has offices in th...
01.12.2004	India goes from strength to strength	The Indian pharmaceutical industry is going from strength to strength in establishing itself across the world. That’s the verdict of Chiltern International, a leading independent clinical research organisation which is carrying out a range ...
25.10.2004	Landmark growth for Chiltern International	Leading independent CRO, Chiltern International celebrated a landmark this week with the announcement that its US operation had passed the 100-employee mark. The company is enjoying a strong and consistent period of growth in the United Sta...
14.10.2004	Chiltern project leader addresses eminent scientific audience on Malaria	Chiltern International clinical project leader and malaria researcher Beatriz Mosqueira has delivered an important seminar on the disease held at IX European Multicolloquium of Parasitology (EMOP IX) in Valencia recently. Malaria constitute...
05.10.2004	Singapore strives for success	A strong commitment to raising its profile and attracting major companies from the pharmaceutical and biotechnology sectors is helping Singapore emerge as a centre for drug Research and Development. As the pharmaceutical industry expands it...
04.08.2004	Chiltern International Opens New Italian Office	Chiltern International is delighted to announce the opening of its new Italian office in Milan. “With a population of almost 58 million, it is not surprising that Italy represents one of the major European countries for clinical trials,” ex...
20.07.2004	Fighting deadly diseases with a distant impact	Dr Faiz Kermani, Chiltern International Although tropical and resurgent infectious diseases are most often associated with Africa, Asia and Latin America increased global travel and trade between regions has led to a growing number of cases...
14.07.2004	Sir Richard Sykes Opens Chiltern’s New Global HQ	SLOUGH, UK – 14 July 2004 - Leading independent clinical research organisation Chiltern International today welcomed Sir Richard Sykes, Rector of Imperial College London, as its guest of honour for the official opening of its new global hea...
13.07.2004	The European Pharma industry: Converting brain drain into brain gain	As pharmaceutical companies expand and the decision-making processes become increasingly complex, the presence of individuals who can effectively and intelligently communicate ideas and results will help to influence the overall performance...
06.07.2004	France Fights for its Pharma Future	Dr Faiz Kermani, Chiltern International Introduction France has been one of the major forces in the European pharmaceutical industry. According to the French pharmaceutical industry body, LEEF (Les entreprises du medicament), since 1995, Fr...
14.06.2004	Outsourcing the way to control spiraling R&D budgets?	Companies developing new drugs for the global market must deal with the rising costs of the R&D process – and outsourcing may well be the best route. That's the verdict of Dr Faiz Kermani, a specialist in outsourcing and research develo...
02.06.2004	Chiltern highlights the importance of tackling one of the world’s ‘neglected killers’	It's Africa's biggest killer, but it's not HIV. It causes economic losses of US$12 billion per year, but it's not a war. And it has slowed African economic growth by around 1.3 per cent per annum, but it’s not a famine. The guilty party is ...
20.05.2004	Canada Outlook Excellent	Leading independent CRO Chiltern International is reporting significant increases in demand for its services in Canada, and believes the country's pharmaceutical market presents real opportunities. The pharmaceutical and biotech sectors are...
21.04.2004	Turkey Exhibits Potential For Clinical Trials	Turkey is transforming into an attractive place to conduct clinical trials. That's the verdict of Christine Ott of leading independent CRO Chiltern International, which has shown the potential of running trials in less traditional countries...
11.03.2004	Chiltern Participates in French Government Initiative as it Plans France’s Future in Pharma R&D	Chiltern International - the largest independent global Clinical Research Organisation - has been consulted by a delegation from the French Economic Ministry in an attempt by the Government to boost France's standing in the international he...
02.03.2004	Long Term Strategy The Key To Success	Dr Faiz Kermani of Chiltern International, the largest independent global Clinical Research Organisation, recently commented on the complex relationship between long-term R&D strategies and success in new drug productivity, and conclude...
-	Global CRO market to grow to $57 billion by 2024, report forecasts	For drug companies large and small that are running clinical trials, it’s often essential to outsource some or even all a trial’s functions to third-party vendors. And with clinical trials expected to grow in number and complexity, those ve...

Chiltern

Investors 1

Mentions in press and media 23

Reviews 0